The pooled results show that the use of anti-VEGFR agents is associated with a significantly increased risk of developing grade ≥3 hypertension and FAEs in comparison with controls, whereas no significant relationship is found between anti-VEGFR agents use and risk of GI perforation, ATEs or VTEs, or hemorrhagic events. This evidence concerns the gene KDR and Hypertension.